Glucotrack forms Patient Advisory Board to guide implantable CBGM development

Glucotrack, Inc.

Patient Advisory Board (PAB) formed with leading diabetes patient advocates and voices.
Inaugural PAB meeting held on May 3, 2025; will convene regularly.
PAB aims to keep patient insights at the forefront of long-term implantable CBGM development.
CBGM is designed for up to 3 years of continuous blood glucose monitoring, no wearable component.
CBGM is an Investigational Device limited by federal law to investigational use.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.